ANI Pharmaceuticals (ANIP) Competitors

ANI Pharmaceuticals (NASDAQ:ANIP) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations and institutional ownership.

Do institutionals & insiders believe in ANIP or ADMA?

76.1% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 11.1% of ANI Pharmaceuticals shares are owned by company insiders. Comparatively, 3.5% of ADMA Biologics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Does the media prefer ANIP or ADMA?

In the previous week, ANI Pharmaceuticals had 26 more articles in the media than ADMA Biologics. MarketBeat recorded 38 mentions for ANI Pharmaceuticals and 12 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 1.59 beat ANI Pharmaceuticals' score of 0.64 indicating that ADMA Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ANI Pharmaceuticals	17 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
ADMA Biologics	12 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Do analysts prefer ANIP or ADMA?

ANI Pharmaceuticals currently has a consensus price target of $84.75, indicating a potential downside of 6.88%. ADMA Biologics has a consensus price target of $27.67, indicating a potential upside of 55.43%. Given ADMA Biologics' stronger consensus rating and higher probable upside, analysts clearly believe ADMA Biologics is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00
ADMA Biologics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33

Which has more volatility & risk, ANIP or ADMA?

ANI Pharmaceuticals has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.38, meaning that its stock price is 62% less volatile than the S&P 500.

Which has stronger valuation and earnings, ANIP or ADMA?

ADMA Biologics has lower revenue, but higher earnings than ANI Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$614.38M	3.21	-$18.52M	-$0.77	-118.19
ADMA Biologics	$426.45M	9.96	$197.67M	$0.86	20.70

Is ANIP or ADMA more profitable?

ADMA Biologics has a net margin of 44.06% compared to ANI Pharmaceuticals' net margin of -1.37%. ADMA Biologics' return on equity of 41.01% beat ANI Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	-1.37%	25.03%	8.00%
ADMA Biologics	44.06%	41.01%	28.47%

Summary

ADMA Biologics beats ANI Pharmaceuticals on 10 of the 16 factors compared between the two stocks.